Use of high-throughput LC-MS/MS proteomics technologies in drug discovery

Zhouxin Shen; Ming-Wei Wang; Steven P Briggs

doi:10.1016/j.ddtec.2006.09.007

Use of high-throughput LC-MS/MS proteomics technologies in drug discovery

Drug Discov Today Technol. 2006 Autumn;3(3):301-6. doi: 10.1016/j.ddtec.2006.09.007.

Authors

Zhouxin Shen¹, Ming-Wei Wang², Steven P Briggs³

Affiliations

¹ Section of Cell & Developmental Biology, Division of Biological Sciences, University of California, San Diego, Natural Science Building, Room 6320, 9500 Gilman Drive, La Jolla, CA 92093-0380, USA.
² The National Center for Drug Screening, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 189 Guo Shou Jing Road, Zhangjiang High-Tech Park, Shanghai 201203, PR China.
³ Section of Cell & Developmental Biology, Division of Biological Sciences, University of California, San Diego, Natural Science Building, Room 6320, 9500 Gilman Drive, La Jolla, CA 92093-0380, USA. Electronic address:[email protected].

PMID: 24980532
DOI: 10.1016/j.ddtec.2006.09.007

Abstract

Significant improvements have been made during the past few years in technologies for high-throughput proteomics based on mass spectrometry. As proteomics technologies advance and become more widely accessible, efforts to profile and quantify full proteomes are underway to complement other genomics approaches, such as transcript and metabolite profiling. Of particular interest is the application of proteomics to protein biomarker discovery, which is increasingly being recognized as crucially important for the study of disease processes, both from the diagnostic and prognostic points of view. This review will discuss the advances and current limitations of full proteome analysis for biomarker discovery, including deep proteome profiling, quantitative proteomics, and phosphoproteome profiling.: